Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

10.69
-0.2100-1.93%
Post-market: 10.690.00000.00%19:43 EDT
Volume:748.54K
Turnover:8.13M
Market Cap:931.71M
PE:-5.02
High:11.24
Open:10.90
Low:10.65
Close:10.90
52wk High:36.26
52wk Low:5.36
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.64
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:2.16
PE(LYR):-5.72

Loading ...

Olema Pharmaceuticals to present two preclinical posters at AACR Annual Meeting

Reuters
·
Mar 18

Olema Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 17

Guggenheim Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Mar 17

Olema Oncology price target raised to $62 from $60 at Citi

TIPRANKS
·
Mar 17

Olema Pharmaceuticals: Palazestrant Phase III Upside and Differentiated Pipeline Underpin Buy Rating

TIPRANKS
·
Mar 17

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Mar 17

Olema Pharmaceuticals Shares Rise on Narrower Loss Per Share in 2Q

Dow Jones
·
Mar 17

Buy Rating Reaffirmed on Palazestrant’s Differentiated Phase 3 Program and Favorable Risk‑Reward Profile for Olema

TIPRANKS
·
Mar 16

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Weigh Tech Rally Against Geopolitical Risks

MT Newswires Live
·
Mar 16

Olema Pharmaceuticals Q4 EPS $(0.50) Beats $(0.53) Estimate

Benzinga Earnings
·
Mar 16

Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs

Reuters
·
Mar 16

Olema Q4 net loss widens 37.2% to USD 46.06 million

Reuters
·
Mar 16

BRIEF-Olema Pharmaceuticals Q4 Net Income USD -46.061 Million

Reuters
·
Mar 16

Olema Pharmaceuticals Q4 EPS USD -0.5

THOMSON REUTERS
·
Mar 16

Olema Pharmaceuticals Q4 Income From Operations USD -50.084 Million

THOMSON REUTERS
·
Mar 16

Olema Pharmaceuticals Inc - to Report Phase 3 Opera-01 Top-Line Data in Fall 2026

THOMSON REUTERS
·
Mar 16

Olema Pharmaceuticals Inc - Continues Enrollment in Phase 1 Study of Op-3136; Initial Data Expected Q2 2026

THOMSON REUTERS
·
Mar 16

Press Release: Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Dow Jones
·
Mar 16

Olema Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters
·
Mar 13

What's Going On With Olema Pharmaceuticals Stock On Wednesday?

Benzinga_recent_news
·
Mar 11